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ed March 4, 2014.he aim of this study was to investigate the impact of atrial ﬁbrillation (AF) and antithrombotic treatment on
the prognosis in patients with heart failure (HF) as well as vascular disease.Background HF, vascular disease, and AF are pathophysiologically related, and understanding antithrombotic treatment for
these conditions is crucial.Methods In hospitalized patients with HF and coexisting vascular disease (coronary artery disease or peripheral arterial
disease) followed from 1997 to 2009, AF status was categorized as prevalent AF, incident AF, or no AF. Risk of
thromboembolism (TE), myocardial infarction (MI), and serious bleeding was assessed by Cox regression models
(hazard ratio [HR] with 95% conﬁdence interval [CI]) with antithrombotic therapy and AF as time-dependent variables.Results A total of 37,464 patients were included (age, 74.5  10.7 years; 36.3% females) with a mean follow-up of 3 years
during which 20.7% were categorized as prevalent AF and 17.2% as incident AF. Compared with vitamin K
antagonist (VKA) in prevalent AF, VKA plus antiplatelet was not associated with a decreased risk of TE (HR: 0.91;
95% CI: 0.73 to 1.12) or MI (HR: 1.11; 95% CI: 0.96 to 1.28), whereas bleeding risk was signiﬁcantly increased (HR:
1.31; 95% CI: 1.09 to 1.57). Corresponding estimates for incident AF were HRs of 0.77 (95% CI: 0.56 to 1.06), 1.07
(95% CI: 0.89 to 1.28), and 2.71 (95% CI: 1.33 to 2.21) for TE, MI, and bleeding, respectively. In no AF patients, no
statistical differences were seen between antithrombotic therapies in TE or MI risk, whereas bleeding risk was
signiﬁcantly increased for VKA with and without single-antiplatelet therapy.Conclusions In AF patients with coexisting HF and vascular disease, adding single-antiplatelet therapy to VKA therapy is
not associated with additional beneﬁt in thromboembolic or coronary risk, but notably increased bleeding risk.
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Two conditions commonly related to HF are vascular
disease and atrial ﬁbrillation (AF), with both frequently
requiring the use of antithrombotic therapy with antiplatelet
drugs and oral anticoagulation, respectively. In patients with
coronary or peripheral artery disease, antiplatelet therapy
is recommended (5–7), although the beneﬁts of antiplatelet
therapy in patients with concomitant HF are less well deﬁned
in relation to mortality and vascular events (4). In HF pa-
tients with AF, oral anticoagulation is clearly indicated (8,9).
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CHA2DS2-VASc = congestive
heart failure, hypertension,
older than 75 years of age,
diabetes, stroke/
thromboembolism, vascular
disease, 65 to 74 years or
age, female sex
CI = conﬁdence interval
HAS-BLED = hypertension,
abnormal liver/renal
function, stroke, bleeding,
labile international
normalized ratio, elderly,
drugs
HF = heart failure
HR = hazard ratio
ICD = International
Classiﬁcation of Diseases
INR = international
normalized ratio
TE = thromboembolism
VKA = vitamin K antagonist
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2690The use of antithrombotic
therapy has to balance a reduc-
tion in TE against the potential
increase in risk of bleeding (10).
Bleeding while on antithrombotic
therapy may have implications
for subsequent adverse outcomes
(11–15). Patients with HF may
also be predisposed to more
bleeding due to difﬁculties with
warfarin and liver congestion
(16), and in the recent WAR-
CEF (Warfarin versus Aspirin
in Reduced Cardiac Ejection
Fraction) trial conducted in HF
patients in sinus rhythm, the
beneﬁcial effects of reducing
ischemic stroke were offset by an
increase in major bleeding with
warfarin therapy (17).
If patients with HF have both
vascular disease and AF, a com-
mon practice is to concomitantly
prescribe oral anticoagulation and
antiplatelet therapy because suchpatients are considered high risk. Indeed, incident and
prevalent AF may confer different risks. In general popula-
tion studies, there is little evidence of a beneﬁcial effect of
such combination antithrombotic therapy on TE, given the
increase in serious bleeding (11,12). Limited data are avail-
able for HF patients who have both vascular disease and AF.
In a real-life cohort of HF patients with vascular disease,
our objective was to assess the relationship of incident or
prevalent AF to TE and serious bleeding. Second, we also
assessed the effectiveness and safety of ongoing antith-
rombotic treatment in such patients.Methods
Registries. We linked information on the individual level
from several nationwide databases. The National Patient
Registry classiﬁes all hospital contacts according to the In-
ternational Classiﬁcation of Diseases (ICD) since 1977 (with
the eighth revision until 1994 and then the 10th revision.).
Coding is performed for the primary diagnosis of contact,
and, if appropriate, 1 secondary diagnoses, and when
identifying diagnoses in the registries was allowed (18).
Procedures performed are also coded according to Nordic
Medical Statistics Committee of Surgical Procedures. From
the national prescription registry, we collected information on
the dose, number of tablets, and date of dispensing for each
individual according to the Anatomical Therapeutic Chem-
ical Classiﬁcation system endorsed by the World Health
Organization (19). Vital status and cause of death according
to the ICD 10th revision were obtained from the Danish
Personal Registration System and the National Causes ofDeath register, respectively (20). Using a unique number, we
retrospectively linked this information for each individual. All
ICD and Anatomical Therapeutic Chemical Classiﬁcation
system codes used are available in the Online Table 1.
Study population. All Danish residents with a ﬁrst-time HF
hospitalization between January 1, 1997 and December 31,
2009 were identiﬁed. We included patients with a previous
diagnosis of myocardial infarction (MI), aortic plaque, and
peripheral artery disease and having undergone procedures
on coronary arteries (coronary artery bypass and coronary
intervention) as markers of vascular disease. The date of
study inclusion of patients with HF was the date of
discharge. The presence of no AF included patients without
an AF diagnosis (since 1977) before HF hospitalization,
whereas prevalent AF patients had a diagnosis of AF before
hospitalization for HF. During the study period, no
AF patients were continuously screened for an AF diagnosis
and categorized as incident AF at the date of a ﬁrst-time AF
admission. Hence, the study population initially comprised
patients with a HF hospitalization and coexisting vascular
disease with status of prevalent (known) AF or no AF.
During follow-up, the status of no AF patients could sub-
sequently change to incident AF (Fig. 1). Categorizing AF
patients was predeﬁned as the occurrence of AF (either
prevalent or incident) from a ﬁrst-time HF hospitalization
might pose different risks (e.g., duration of AF disease
burden, inﬂuencing antithrombotic treatment strategy, pro-
gression of HF).
Heart failure. The administrative discharge coding for HF
classiﬁed HF as hypertensive (ICD-10 DI11.0), cardiomy-
opathy (ICD-10 DI42, including dilated, alcoholic, and
obstructive cardiomyopathy), acute pulmonary edema
(ICD-10 DJ81.9), and unspeciﬁed HF (ICD-10 DI50
including decompensated HF [ICD-10 I50.9]). To assess
the severity of HF, we calculated the daily dose of loop
diuretics before and after HF hospitalization: group 1 (0 to
39 mg), group 2 (40 mg to 79 mg), group 3 (80 mg to
159 mg), and group 4 (160 mg), as previously done (21).
Antithrombotic treatment. For each individual, all pre-
scriptions of aspirin, clopidogrel, and vitamin K antagonists
(VKA) (i.e., warfarin and phenprocoumon) were identiﬁed,
and the following commonly used treatment regimens were
classiﬁed: single-antiplatelet therapy (aspirin or clopidogrel),
VKA, and VKA plus single-antiplatelet therapy. In no
AF patients, dual-antiplatelet therapy (aspirin and clopi-
dogrel) was also assessed for the primary outcomes. Ongoing
antithrombotic treatment was determined from claimed
prescriptions as previously done (11,22). Brieﬂy, from the
number of tablets dispensed and the strength of tablets,
the average daily dose was deﬁned. Patients were allowed
to change group but could only be exposed to 1 treatment
group at any given time and were only considered at risk
when having tablets available for consumption. Subsequent
antithrombotic treatment at baseline was deﬁned as any
claimed prescriptions of VKA, antiplatelet drugs, or both up
to 30 days after HF discharge (11).
Figure 2
Prognosis in First-Time Hospitalized Heart Failure
Patients With Vascular Disease According to the
Presence of Atrial Fibrillation
Kaplan-Meier survival estimates adjusted for age (75 years).
Figure 1 Study Population
Heart failure patients with coexisting vascular disease were categorized as
prevalent or no atrial ﬁbrillation at inclusion. Patients with no atrial ﬁbrillation were
continuously screened for incident atrial ﬁbrillation during follow-up, and their
status could change accordingly.
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2691Outcomes. TE was deﬁned as hospitalization or death
caused by ischemic stroke, transient ischemic attack, and
arterial embolism. Serious bleeding was deﬁned as hospi-
talization or death caused by intracranial, gastrointestinal,
respiratory, and urogenital bleeding and anemia caused by
bleeding. As secondary outcomes, recurrent HF hospitali-
zation and MI including hospitalization and coronary death
were used. Due to study design of continuous inclusion of
incident AF, death was included as an outcome for prevalent
AF and no AF patients only. The outcome deﬁnitions were
previously used (22–24). For overall thrombosis risk, an
outcome including both TE and MI was also deﬁned.
Other pharmacotherapy and comorbidity. Any pre-
scriptions 180 days before inclusion of the following drugs
deﬁned other pharmacotherapy: renin-angiotensin inhibi-
tors, beta-blockers, spironolactone, thiazides, loop diuretics,
nonsteroidal anti-inﬂammatory drugs, and statins. For risk
factors for TE and bleeding, we calculated scores of
CHA2DS2-VASc (congestive HF, hypertension, age older
than 75 years, diabetes, stroke/TE, vascular disease, 65 to
74 years of age, female sex) and HAS-BLED (hypertension,
abnormal liver/renal function, stroke, bleeding, labile inter-
national normalized ratio [INR], elderly, drugs [non-steroidal
anti-inﬂammatory drugs]) from recorded comorbidities and
pharmacotherapy as previously used and validated (23,25).
All patients were scored at least 2 for CHA2DS2-VASc
according to HF and vascular disease status. INR values
were not available in the registries, and use of aspirin was
not incorporated in the (modiﬁed) HAS-BLED score, as
this was an explanatory variable. For incident AF patients,
all characteristics were determined at the date of the ﬁrst-
time AF diagnosis.
Statistical analyses. Continuous variables are presented
as mean  SD, and categorical variables as number(percentage). All rates are crude incidence rates calculated as
events per 100 person-years with 95% conﬁdence intervals
(CIs). Hazard ratio (HR) estimates with 95% CIs for out-
comes were calculated in a Cox proportional hazard model
with antithrombotic treatment and AF status as time-varying
variables. These models were adjusted for age, sex, inclusion
year, HF severity group (daily dose of loop diuretics at in-
clusion), and CHA2DS2-VASc score for events of TE
and HAS-BLED for events of serious bleeding. For the
secondary outcomes, adjustment included evidence-based HF
medication (beta-blockers, renin-angiotensin receptor in-
hibitors, and spironolactone) for HF hospitalization, and
coronary risk factors/medication (beta-blockers, renin-
angiotensin receptor inhibitors, statins, diabetes, hyperten-
sion, and renal failure) for events of MI. In models not
assessing antithrombotic treatment, ongoing antithrombotic
treatment was also used for adjustment. As mentioned
previously, characteristics were updated in patients changing
from no AF to incident AF status. To illustrate the overall
prognosis in the population, we calculated Kaplan-Meier
survival estimates for patients with prevalent AF and no
AF at inclusion (the no AF group comprised subsequently
incident AF patients) (Fig. 2). For sensitivity and the po-
tential reduction of unmeasured confounders, we performed
matching analyses using a propensity score model. We
deﬁned controls as no AF patients and cases as the presence
of AF (whether prevalent and incident) and used risk set
matching by date of potential AF. This allowed a patient
without AF to be deﬁned as a control and subsequently as a
case if an AF hospitalization occurred. Propensity score was
calculated by a Cox regression model conditional on baseline
variables of age, inclusion year, and risk factors included in
the CHA2DS2-VASc and HAS-BLED scores. Matching
was performed using the Greedy matching macro. Patients
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2692were followed to death or the end of the study period
(December 31, 2009). For model control, assumptions were
not violated (linearity of continuous variables, proportional
hazard assumptions, and lack of clinical relevant inter-
action). Statistical software packages SAS version 9.2 (SAS
Institute, Inc., Cary, North Carolina) and Stata version
11.0 (StataCorp, College Station, Texas) were used.
Ethics. The study was approved by the Danish Data Pro-
tection agency (ref 2007-41-1667), and data were made
available to us so no individuals could be identiﬁed. As aTable 1 Characteristics of the Study Population
No AF
Total 29,660
Female patients 36.4
Age, yrs 73.9  11
Vascular disease
Diagnosis 93.5
Procedure 27.3
Heart failure discharge diagnosis
Hypertensive 2.3
Cardiomyopathy 3.0
Decompensated 32.0
Acute pulmonary edema 3.8
Unspeciﬁed 58.9
Severity group (at/after inclusion)
1 60.8/38.1
2 19.1/17.9
3 15.3/32.4
4 4.9/11.6
CHA2DS2-VASc score 4.9  1.5
2 4.2
3 12.7
4 23.6
5 26.9
6 18.7
7 9.4
>7 4.4
HAS-BLED 2.1  1.0
Low (score 0-1) 30.3
Intermediate (score 2) 38.5
High (score 3) 31.2
Other pharmacotherapy
RAS inhibitors 51.7
Beta-blockers 45.7
Loop diuretics 55.9
Statins 39.3
Spironolactone 14.4
Glucose-lowering medication 18.0
NSAIDs 21.3
Subsequent antithrombotic treatmenty
Antiplatelet 36.3
Vitamin K antagonists 7.3
Both 2.6
Values are mean  SD or % (rounded column percentage). *Group is sub
calculated from the date of incident AF. yAt least 1 prescription claimed wi
AF ¼ atrial ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure, hyperten
vascular disease, 65 to 74 years or age, female sex; HAS-BLED ¼ hypertens
normalized ratio, elderly, drugs; NSAIDs ¼ nonsteroidal anti-inﬂammatory dretrospective registry-based study, Danish law does not
require ethical approval.
Results
A total of 37,464 patients with HF and vascular disease
were included (age, 74.5  10.7 years; 36.3% females). Of
these 7,804 (20.7%) had prevalent AF, whereas in another
6,432 (17.2%) incident AF developed (Fig. 1). The charac-
teristics of the study population according to AF statusPrevalent AF Incident AF*
7,804 6,432
35.7 34.9
.0 76.8  9.3 76.8  9.4
90.3 94.0
31.5 23.4
2.1 2.4
3.0 2.7
31.1 32.9
2.5 2.9
61.4 59.1
55.2/38.0 58.4/1.5
18.9/15.8 22.4/20.4
18.8/31.7 15.2/35.8
7.1/14.5 4.3/12.3
5.3  1.4 5.2  1.4
1.5 1.7
7.9 9.3
21.3 21.2
26.9 27.9
21.7 21.8
13.5 12.0
7.1 6.1
2.3  1.0 2.3  1.0
20.1 21.8
39.6 39.8
40.3 38.4
55.5 59.7
55.6 52.2
66.5 71.6
41.7 42.1
17.7 23.2
17.8 17.6
18.6 19.3
29.2 30.3
20.7 25.0
6.0 8.0
group of the no AF group, and all scores and pharmacotherapy are
thin 30 days after discharge.
sion, older than 75 years of age, diabetes, stroke/thromboembolism,
ion, abnormal liver/renal function, stroke, bleeding, labile international
rugs; RAS ¼ renin-angiotensin system.
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2693(no, prevalent, or incident AF) are shown in Table 1. In
patients with no AF, potential indications for antith-
rombotic therapy are provided in Online Table 2. The mean
time between the date of the ﬁrst hospitalization for vas-
cular disease and inclusion (with HF) was 6.5  6.5 years,
with a median of 4.5 years (interquartile range: 0.8 to 10.5
years). The mean CHA2DS2-VASc and HAS-BLED
scores were 5.0  1.5 and 2.1  1.0, respectively. During
a mean follow-up of 3 years (median, 3.3 years; interquartile
range: 0.9 to 7.9 years), 23,154 (61.8%) patients died.
Prevalent AF patients were more likely to die compared with
no AF patients (Fig. 2). A total of 4,272 (11.4%), 4,383
(11.7%), 17,889 (47.7%), and 13,003 (34.7%) events of TE,
serious bleeding, recurrent HF hospitalization and MI,
respectively, occurred.
Relationship of AF status to outcomes. The total number
of person-years accumulated for prevalent AF was 20,691
and 15,758 person-years for incident AF. The no AF group
accumulated 77,317 person-years. The mean time to inci-
dent AF was 473  787 days with a median 56 days
(interquartile range, 0 to 632 days). Crude rates of TE
(events per 100 person-years were 5.8 [95% CI: 5.5 to 6.2],
4.6 [95% CI: 4.2 to 5.0], and 4.1 [95% CI: 3.9 to 4.2]) for
prevalent, incident, and no AF, respectively. For serious
bleeding, the corresponding crude rates were 5.6 (95% CI:
5.3 to 6.0), 4.6 (95% CI: 4.3 to 5.0), and 3.7 (95% CI: 3.5 to
3.8). Figures 3A and 3B show that incident and prevalent
AF had similar HRs of TE and serious bleeding, and the
risk was higher than in patients without AF. For the sec-
ondary outcomes of HF hospitalization and MI, crude rates
and HRs are shown in Figures 3C and 3D. Among patients
with either prevalent or incident AF, no marked difference
was apparent for the risk of recurrent HF hospitalization.
With regard to the risk of MI, an increased risk was seen
for incident AF compared with no AF or prevalent AF. No
clinically relevant effect modiﬁcation was present for the
use of evidence-based HF medication (beta-blockers, renin-
angiotensin receptor inhibitors, and spironolactone) among
AF patients compared with no AF patients. In the pro-
pensity score–matched model, the risk of TE (HR: 1.29;
95% CI: 1.20 to 1.38) and bleeding (HR 1.48; 95% CI: 1.38
to 1.60) among patients with AF compared with patients
without AF resembled the main analyses.
Relationship to antithrombotic therapy according to AF
status on the risk of TE and serious bleeding. Among
HF patients with coexisting vascular disease and prevalent
AF, TE rates were highest among those on single-antiplatelet
therapy and lowest for VKA plus single-antiplatelet therapy
(Fig. 3A). No statistical difference in the risk of TE was
found for VKA plus single-antiplatelet therapy compared
with VKA (HR: 0.91; 95% CI: 0.73 to 1.12). Bleeding risk
was signiﬁcantly increased for VKA plus single-antiplatelet
therapy compared with VKA alone (HR: 1.31; 95% CI:
1.09 to 1.57) (Fig. 3B). In HF patients with incident AF,
TE rates were higher among those on antiplatelet therapy
and lowest in those with combined VKA and antiplatelettherapy. Bleeding risk was greater in patients with VKA plus
single-antiplatelet therapy compared with those on VKA-
only therapy. Among HF patients with no AF, the risk of
TE was similar between single-antiplatelet therapy, VKA,
and VKA plus single-antiplatelet therapy. Bleeding risk
was lowest in single-antiplatelet therapy and highest in VKA
plus single-antiplatelet therapy. For fatal bleedings only,
no differences were seen between the antithrombotic ther-
apies (data not shown), although increased crude rates for
prevalent (0.8 events per 100 person-years) and incident (0.7
events per 100 person-years) AF were seen compared with
no AF patients (0.4 events per 100 person-years). Dual-
antiplatelet therapy (aspirin and clopidogrel) was frequently
used in no AF patients (4,608 person-years accumulated),
and crude rates were 3.5 (95% CI: 3.0 to 4.1) and 5.5 events
per 100 person-years (95% CI: 4.8 to 6.2) of TE and
bleeding, respectively. Regarding single-antiplatelet therapy,
the risk of TE was signiﬁcantly reduced (HR: 0.82; 95% CI:
0.69 to 0.97), whereas the risk of bleeding was signiﬁcantly
increased (HR: 1.53; 95% CI: 1.33 to 1.76) when on dual-
antiplatelet therapy.
Relationship to antithrombotic therapy according to AF
status on secondary outcomes. In patients without AF,
VKA and VKA plus single-antiplatelet therapy were asso-
ciated with an increased risk of HF hospitalization com-
pared with single-antiplatelet therapy. No difference was
found between VKA plus single-antiplatelet therapy and
VKA-only therapy (Fig. 3C). Among AF patients, no sig-
niﬁcant differences were found between antithrombotic
treatment regimens, although adding a single antiplatelet to
VKA was associated with an HR of 1.11 (95% CI: 1.00 to
1.23) for risk of HF hospitalization in prevalent AF pa-
tients. Regardless of AF status, no statistically signiﬁcant
difference was found between VKA plus single-antiplatelet
therapy and VKA-only therapy regarding the risk of MI
(Fig. 3D). Among AF patients, single-antiplatelet therapy
was associated with increased risk of MI. For the combined
outcome of TE and MI, no statistical difference was found
for VKA plus single-antiplatelet therapy compared with
VKA-therapy for prevalent (HR: 1.00; 95% CI: 0.89 to
1.14) or incident AF (HR: 0.97; 95% CI: 0.82 to 1.14)
(Online Table 3).
Discussion
In this study, we show that among patients with HF and
vascular disease, the presence of incident and prevalent AF
conferred similar HRs of TE, which was greater than those
with no AF. However, the risk of serious bleeding for
incident and prevalent AF was particularly high when a
single antiplatelet was added to VKA therapy. Second, we
show that among patients with no AF, there was no dif-
ference between antiplatelet therapy and VKA therapy for
TE, but serious bleeding increased with VKA therapy.
AF contributes to a high risk of stroke and TEs in HF,
and our data support previous studies (26,27). For either
Figure 3 Risk of Outcomes
Risk of thromboembolism (A), serious bleeding (B), heart failure hospitalization (C), and myocardial infarction (D) according to AF status and antithrombotic therapy. Rates are
events per 100 person-years with 95% CI. Adjusted for age, sex, inclusion year, heart failure severity group and CHA2DS2-VASc (congestive heart failure, hypertension, older than
75 years of age, diabetes, stroke/thromboembolism, vascular disease, 65 to 74 years or age, female sex) (for thromboembolism), HAS-BLED (hypertension, abnormal liver/
renal function, stroke, bleeding, labile international normalized ratio, elderly, drugs) (for serious bleeding), evidence-based pharmacotherapy (for heart failure hospitalization)
and coronary risk factors/medication (myocardial infarction). Single AP denotes either aspirin or clopidogrel. All p values denote tests for difference. AF ¼ atrial ﬁbrillation;
AP ¼ antiplatelet; CI ¼ conﬁdence interval; HR ¼ hazard ratio; VKA ¼ vitamin K antagonists. Continued on the next page.
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2694prevalent or incident AF, we found similar risks of TE,
serious bleeding, and HF hospitalization, suggesting that
regardless of the ﬁrst appearance of AF, the prognosis is
worsened for these speciﬁc outcomes. Incident AF was
associated with an increased risk of coronary events, whereasprevalent AF was not compared with no AF. It has been
suggested that AF could be a marker of disease progression,
and our ﬁndings support previous studies that found that
new-onset AF was independently associated with cardio-
vascular events and death in both healthy individuals and
Figure 3 Continued
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2695HF patients (28,29). HF, whether due to reduced ejection
fraction or preserved ejection fraction, has been associated
with TE, especially when AF is present. Indeed, the C in
the CHA2DS2-VASc score refers to recent acute decom-
pensated HF or the presence of moderate to severe left
ventricular dysfunction (30). Nonetheless, reliance on diag-
nostic coding of any HF may be less reliable because only
w50% of such patients actually have conﬁrmed HF in the
primary care setting (8,31). Although a considerable higher
predictive value of HF has been found in hospitalizedpatients, the risk and mechanisms of thrombosis related to
the type and degree of HF are still unresolved (32). Un-
surprisingly, any HF did not emerge as an independent
stroke risk factor in the large Swedish AF cohort study (33),
but has been associated with TE in other AF populations
(23). AF carries a particularly poor prognosis in HF patients,
with mortality being signiﬁcantly greater with AF compared
with no AF, as shown in our nationwide cohort study.
Importantly, we show a beneﬁcial impact of VKA therapy in
these patients with regard to TE protection compared with
Lamberts et al. JACC Vol. 63, No. 24, 2014
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2696single-antiplatelet therapy, and even in the historical trials,
VKA therapy signiﬁcantly reduced all-cause mortality by
26% (34).
The use of antithrombotic therapy has to balance the
reduction in TE with an increase in bleeding risk. Our data
show that among HF patients with no AF, there is no
difference between antiplatelet therapy and VKA therapy for
TE, but serious bleeding is signiﬁcantly less. These ﬁndings
are supportive of the recent European Society of Cardiology
guidelines on HF, which give a class III recommendation on
the use of VKA therapy in HF patients without AF with
regard to thrombosis protection (8). This is also consistent
with observations in WARCEF, which showed a signiﬁcant
reduction in ischemic stroke with VKA therapy but at the
cost of greater major bleeding risk (17). As expected, the
combination of VKA and antiplatelet therapy is associated
with an even higher bleeding risk. In the presence of AF
(whether prevalent or incident), VKA-treated patients with
HF had lower TE compared with antiplatelet therapy, with
a higher bleeding risk. When the analysis was conﬁned to
fatal bleeds only, the difference between VKA therapy and
single-antiplatelet therapy was nonsigniﬁcant. Patients with
previous vascular disease are at increased risk of a coronary
event, and we also assessed whether combination therapy of
VKA and a single antiplatelet agent might provide further
protection from MI. In both AF and no AF patients, we did
not ﬁnd statistical difference between VKA with or without
a single antiplatelet agent, suggesting adequate coronary
prophylaxis with VKA-only therapy. Our data support
ﬁndings from a previous controlled trial of the favorable
efﬁcacy of VKA (against aspirin and VKA plus aspirin)
during 26 months of follow-up post-MI (35). A meta-
analysis of trials before year 2000 concluded that oral anti-
coagulant therapy (moderate- or high-intensity therapy)
with or without aspirin was beneﬁcial for secondary coronary
artery disease protection, whereas the degree of bleeding
hazard was uncertain (36). Both studies allowed for effects at
different INR levels but were limited because of a small
sample size and did not speciﬁcally include HF patients or
investigate contemporary real-life patients with currently
used treatment regimens.
The endpoint of HF admissions and death is commonly
the primary outcome in HF trials. In our analysis, we chose a
secondary outcome of HF hospitalization (without death) as
prescribed antithrombotic medication would likely be
withdrawn in terminally ill patients. We found that this
outcome was increased in those with AF (whether prevalent
or incident) compared with those with no AF. With regard
to different antithrombotic strategies in AF patients, we
did not ﬁnd signiﬁcant differences in the risk of HF hos-
pitalization. Regarding single-antiplatelet therapy in no
AF patients, we surprisingly found an increased risk of
HF hospitalization with VKA therapy with or without
single-antiplatelet therapy. This contradicts ﬁndings of the
WARCEF trial, which found a nonsigniﬁcant increase in a
secondary outcome of HF hospitalization with aspirintherapy compared with warfarin therapy in HF patients
in sinus rhythm. However, these ﬁndings are readily
explained by the fact that no information was available of
the speciﬁc indication for therapy, and patients receiving
VKA therapy could be considered having a greater disease
burden (e.g., potential nonregistered AF burden). Of note,
use of renin-angiotensin system inhibitors and other HF
evidence-based medication did not inﬂuence antithrombotic
treatment effect in the present population.
Study limitations. This study is limited by its dependence
on retrospective registry data, and inherent in the observa-
tional design, causal interpretation of treatment effects is not
possible. The diagnoses of AF, HF, MI, and ischemic stroke
have been validated in the registries with positive predictive
values of 97%, 81%, 93%, and 97%, respectively (32,37–39).
INR measurements were not available in the registries.
Although actual ongoing VKA exposure was continuously
updated and these data demonstrated everyday antithrom-
botic treatment strategies, we had no information on the
speciﬁc degree of anticoagulation therapy selected by the
prescribing physicians. As efﬁcacy and hazard have been
shown to be inﬂuenced by target INR levels in especially
controlled settings, this limitation should be acknowledged
when interpreting the results (36). Selection bias could be
present in the no AF group because we did not have data
on silent AF before patients’ initial presentation with their
arrhythmia diagnosis. Thus, the no AF patients may have
included a number of such asymptomatic AF patients who
have an equally poor prognosis as symptomatic patients
(40,41). This is also implied by the high risk of HF hos-
pitalizations in this group and the many patients treated
with VKA therapy despite no registered indication (Online
Table 2). Nonetheless, we clearly show a mortality differ-
ence between prevalent AF compared with no AF patients.
The availability of prolonged electrocardiographic moni-
toring may enable greater detection of AF episodes. We
may also not have accounted for patients with an outpatient
diagnosis of HF who have not been hospitalized. Con-
founding by indication may be present (i.e., patients per-
ceived at higher risk of thrombosis are treated with more
intense antithrombotic therapy). We did not have infor-
mation on the speciﬁc indication for antithrombotic therapy,
and unmeasured confounders could affect the outcomes
under investigation, although we controlled for a wide range
of known risk factors and prophylactic medication for the
speciﬁc outcomes. It should be noted that for the outcome
of MI, all patients were included as having an indication
for antiplatelet therapy but with a wide range and timing of
previous conditions of vascular disease, which could have
affected the antithrombotic treatment prescribed. Conse-
quently, our ﬁndings do not support any recommendation
after an acute ischemic event or after percutaneous coronary
intervention. Finally, compared with other large stroke
prevention trials, our outcomes differentiate strokes into
ischemic and hemorrhagic for better discrimination of the
effectiveness and safety of antithrombotic treatment.
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The presence of AF (prevalent or incident) is an adverse
feature in HF patients with vascular disease, and
arrhythmia has an effect on TE/bleeding and HF hospi-
talizations. No further beneﬁcial effect on TE or coronary
risk was apparent when adding a single antiplatelet agent
to VKA therapy in patients with AF (but with an increase
in bleeding risk), whereas antiplatelet therapy only is
inadequate.
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